

WEST Search History

DATE: Thursday, December 01, 2005

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L21	l2 and antibod\$	1
<input type="checkbox"/>	L20	l3 and l2	0
<input type="checkbox"/>	L19	humoral and l15	0
<input type="checkbox"/>	L18	humoral and l7	38
<input type="checkbox"/>	L17	l7 and l4	61
<input type="checkbox"/>	L16	L15 and l4	0
<input type="checkbox"/>	L15	l7.ab.	83
<input type="checkbox"/>	L14	L13 and l7	2
<input type="checkbox"/>	L13	L12 and l3	494
<input type="checkbox"/>	L12	(435/7.1)![CCLS]	10320
<input type="checkbox"/>	L11	l1 and l7	2
<input type="checkbox"/>	L10	l7 and l4	61
<input type="checkbox"/>	L9	l5 and l4	3711
<input type="checkbox"/>	L8	L7 and l3	20
<input type="checkbox"/>	L7	(HIP NEAR2 l) or (huntingtin interacting protein)	1298
<input type="checkbox"/>	L6	L5 and l3	557
<input type="checkbox"/>	L5	HIP\$ or (huntingtin interacting protein-1)	61921
<input type="checkbox"/>	L4	(detect? or determin\$) near4 antibod?	27480
<input type="checkbox"/>	L3	autoantibod\$	4427
<input type="checkbox"/>	L2	6235879.pn.	1
<input type="checkbox"/>	L1	(ross or mizukami).in.	16182

END OF SEARCH HISTORY

FILE 'MEDLINE' ENTERED AT 07:36:44 ON 01 DEC 2005

L1 139 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L2 49578 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L3 1 S L2 AND L1
L4 32818 S HUMORAL
L5 0 S L4 AND L1
L6 2204 S ELICIT (S) ANTIBOD?
L7 0 S L6 AND L1
L8 701293 S ANTIBOD?
L9 2566559 S SERUM OR SERA OR BLOOD OR URINE
L10 94348 S L9 (S) L8
L11 2 S L10 AND L1

FILE 'CAPLUS' ENTERED AT 07:39:59 ON 01 DEC 2005

L12 173 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L13 18079 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L14 1 S L12 AND L13
L15 2567 S ELICIT (S) ANTIBOD?
L16 448177 S ANTIBOD?
L17 1569955 S SERUM OR SERA OR BLOOD OR URINE
L18 71367 S L16 (S) L17
L19 3 S L18 AND L12

FILE 'PCTFULL' ENTERED AT 07:43:59 ON 01 DEC 2005

L20 203 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L21 3564 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L22 9992 S ELICIT (S) ANTIBOD?
L23 82883 S ANTIBOD?
L24 178963 S SERUM OR SERA OR BLOOD OR URINE
L25 8 S L20 AND L21
L26 6 S L20/AB
L27 25 S L20/CLM
L28 28 S L26 OR L27
L29 0 S L28 AND L21
L30 41122 S L23 (S) L24
L31 55958 S (DETECT? OR DETERMIN?) (S) L23
L32 14 S L31 AND L28
L33 10 S L32 NOT PY>2003
L34 89447 S CANCER? OR TUMOR OR NEOPLAS?
L35 8 S L33 AND L34
L36 12578 S L31/CLM
L37 5 S L36 AND L35
L38 4 S L37 AND L27

FILE 'DISSABS' ENTERED AT 07:50:33 ON 01 DEC 2005

L39 9 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
L40 508 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
L41 0 S L39 AND L40
L42 19247 S ANTIBOD?
L43 7556 S (DETECT? OR DETERMIN?) (S) L42
L44 0 S L43 AND L39
L45 1618 S HUMORAL
L46 0 S L45 AND L39

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:36:33 ON 01 DEC 2005

=> file medline
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'MEDLINE' ENTERED AT 07:36:44 ON 01 DEC 2005

FILE LAST UPDATED: 30 NOV 2005 (20051130/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s (HIP (w) 1) or (huntingtin interacting protein)
      64767 HIP
      6658 HIPS
      65987 HIP
            (HIP OR HIPS)
3594301 1
      86 HIP (W) 1
      949 HUNTINGTIN
      4 HUNTINGTINS
      949 HUNTINGTIN
            (HUNTINGTIN OR HUNTINGTINS)
      27050 INTERACTING
1450747 PROTEIN
1203182 PROTEINS
1838970 PROTEIN
            (PROTEIN OR PROTEINS)
      59 HUNTINGTIN INTERACTING PROTEIN
            (HUNTINGTIN (W) INTERACTING (W) PROTEIN)
L1      139 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)

=> s autoantibod? or (anti () antibod?)
      49366 AUTOANTIBOD?
      583989 ANTI
      6 ANTIS
      583993 ANTI
            (ANTI OR ANTIS)
      701293 ANTIBOD?
      222 ANTI (W) ANTIBOD?
L2      49578 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)

=> s l2 and l1
L3      1 L2 AND L1

=> s humoral
      32817 HUMORAL
      1 HUMORALS
L4      32818 HUMORAL
            (HUMORAL OR HUMORALS)

=> s l4 and l1
L5      0 L4 AND L1

=> s elicit (S) antibod?
```

26267 ELICIT
9942 ELICITS
35347 ELICIT
(ELICIT OR ELICITS)
701293 ANTIBOD?
L6 2204 ELICIT (S) ANTIBOD?

=> s l6 and l1
L7 0 L6 AND L1

=> s antibod?
L8 701293 ANTIBOD?

=> s serum or sera or blood or urine or sample
MISSING TERM AFTER URINE OR
Operators must be followed by a search term, L-number, or query name.

=> s serum or sera or blood or urine
575020 SERUM
4920 SERUMS
118207 SERA
14 SERAS
652274 SERUM
(SERUM OR SERUMS OR SERA OR SERAS)
118207 SERA
14 SERAS
118216 SERA
(SERA OR SERAS)
2148697 BLOOD
618 BLOODS
2148798 BLOOD
(BLOOD OR BLOODS)
235236 URINE
2707 URINES
235631 URINE
(URINE OR URINES)
L9 2566559 SERUM OR SERA OR BLOOD OR URINE

=> s l9 (S) l8
L10 94348 L9 (S) L8

=> s l10 and l1
L11 2 L10 AND L1

=> d ibib 1-2

L11 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 2005258409 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15899803
TITLE: **Serum antibodies to huntingtin
interacting protein-1: a new
blood test for prostate cancer.**
AUTHOR: Bradley Sarah V; Oravec-Wilson Katherine I; Bougeard
Gaelle; Mizukami Ikuko; Li Lina; Munaco Anthony J;
Sreekumar Arun; Corradetti Michael N; Chinnaiyan Arul M;
Sanda Martin G; Ross Theodora S
CORPORATE SOURCE: Department of Internal Medicine, University of Michigan
Medical School, Ann Arbor, Michigan 48109-0942, USA.
CONTRACT NUMBER: R01 CA098730-02 (NCI)
R01 CA82419-01 (NCI)
R01-CA82363-01A1 (NCI)
SOURCE: Cancer research, (2005 May 15) 65 (10) 4126-33.
Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200507
ENTRY DATE: Entered STN: 20050519
Last Updated on STN: 20050708
Entered Medline: 20050707

L11 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 1999408822 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10479128
TITLE: Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons.
AUTHOR: Ellenberger D L; Sullivan P S; Dorn J; Schable C; Spira T J; Folks T M; Lal R B
CORPORATE SOURCE: HIV/AIDS Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.. dxel@cdc.gov
SOURCE: Journal of infectious diseases, (1999 Oct) 180 (4) 1033-42. Journal code: 0413675. ISSN: 0022-1899.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS
ENTRY MONTH: 199911
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991108

=> d ibib kwic 2

L11 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 1999408822 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10479128
TITLE: Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons.
AUTHOR: Ellenberger D L; Sullivan P S; Dorn J; Schable C; Spira T J; Folks T M; Lal R B
CORPORATE SOURCE: HIV/AIDS Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.. dxel@cdc.gov
SOURCE: Journal of infectious diseases, (1999 Oct) 180 (4) 1033-42. Journal code: 0413675. ISSN: 0022-1899.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS
ENTRY MONTH: 199911
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991108

AB . . . (HIV-1)-infected but who remained persistently seronegative (HIPS) on HIV-1 antibody tests were examined through AIDS case surveillance. Six such individuals (HIPS-1 to -4, -7, and -9) were examined to determine whether their persistent seronegativity was attributable to immune dysfunction or infection. . . HIV. Of the 6, 4 had antibody titers to at least 1 other common pathogen. In vitro stimulation of peripheral blood mononuclear cells from HIPS-4 and HIPS-7 with pokeweed mitogen or phosphorothioate oligodeoxynucleotide (direct B cell mitogen) did not produce HIV-1-specific antibody. Reconstitution experiments with recombinant interleukin (rIL)-4 and rIL-12 also had no impact on antibody production. Virus isolates from HIPS-4 and. . .

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.46	2.67

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:39:59 ON 01 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2005 VOL 143 ISS 23
FILE LAST UPDATED: 30 Nov 2005 (20051130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s (HIP (w) 1) or (huntingtin interacting protein)
11220 HIP
1823 HIPS
12705 HIP
(HIP OR HIPS)
8477265 1
67 HIP (W) 1
999 HUNTINGTIN
83 HUNTINGTINS
1015 HUNTINGTIN
(HUNTINGTIN OR HUNTINGTINS)
77642 INTERACTING
1810847 PROTEIN
1263057 PROTEINS
2105815 PROTEIN
(PROTEIN OR PROTEINS)
113 HUNTINGTIN INTERACTING PROTEIN
(HUNTINGTIN (W) INTERACTING (W) PROTEIN)
L12 173 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)

=> s autoantibod? or (anti () antibod?)
17882 AUTOANTIBOD?
388917 ANTI
9 ANTIS
388924 ANTI
(ANTI OR ANTIS)
448177 ANTIBOD?
211 ANTI (W) ANTIBOD?
L13 18079 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)

=> s l12 and l13
L14 1 L12 AND L13

=> s elicit (S) antibod?

21152 ELICIT
8791 ELICITS
29177 ELICIT
(ELICIT OR ELICITS)

448177 ANTIBOD?
L15 2567 ELICIT (S) ANTIBOD?

=> s antibod?

L16 448177 ANTIBOD?

=> s serum or sera or blood or urine

537399 SERUM
16738 SERUMS
45362 SERA
9 SERAS
561377 SERUM
(SERUM OR SERUMS OR SERA OR SERAS)
45362 SERA
9 SERAS
45368 SERA
(SERA OR SERAS)
1216021 BLOOD
1208 BLOODS
1216155 BLOOD
(BLOOD OR BLOODS)
207583 URINE
4423 URINES
208004 URINE
(URINE OR URINES)

L17 1569955 SERUM OR SERA OR BLOOD OR URINE

=> s l16 (S) l17

L18 71367 L16 (S) L17

=> s l18 and l12

L19 3 L18 AND L12

=> d ibib 1-3

L19 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:430537 CAPLUS

DOCUMENT NUMBER: 143:94728

TITLE: **Serum antibodies to
Huntingtin interacting
protein-1: A new blood test for
prostate cancer**

AUTHOR(S): Bradley, Sarah V.; Oravecz-Wilson, Katherine I.;
Bougeard, Gaelle; Mizukami, Ikuko; Li, Lina; Munaco,
Anthony J.; Sreekumar, Arun; Corradetti, Michael N.;
Chinnaiyan, Arul M.; Sanda, Martin G.; Ross, Theodora
S.

CORPORATE SOURCE: Department of Internal Medicine, University of
Michigan Medical School, Ann Arbor, MI, USA

SOURCE: Cancer Research (2005), 65(10), 4126-4133
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:417568 CAPLUS

DOCUMENT NUMBER: 139:5159

TITLE: Overexpressed in cancer of huntingtin

interacting protein, HIP1,
antibodies, HIP1-encoding nucleic acids, and
diagnostic and therapeutic uses

INVENTOR(S): Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh

PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043566	A2	20030530	WO 2002-US36175	20021112
WO 2003043566	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003124533	A1	20030703	US 2001-7047	20011206
CA 2467459	AA	20030530	CA 2002-2467459	20021112
EP 1527190	A2	20050504	EP 2002-793914	20021112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 2004265929	A1	20041230	US 2004-767325	20040129
WO 2005072457	A2	20050811	WO 2005-US3330	20050128
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-335276P	P 20011115
			US 2001-7047	A 20011206
			WO 2002-US36175	W 20021112
			US 2004-767325	A 20040129

L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:668929 CAPLUS

DOCUMENT NUMBER: 132:150503

TITLE: Viral and immunologic examination of human
immunodeficiency virus type 1-infected, persistently
seronegative persons

AUTHOR(S): Ellenberger, Dennis L.; Sullivan, Patrick S.; Dorn,
Jonathan; Schable, Charles; Spira, Thomas J.; Folks,
Thomas M.; Lal, Renu B.

CORPORATE SOURCE: HIV/AIDS and Retrovirology Branch, Division of AIDS,

STD, and TB Laboratory Research, National Center for,
Atlanta, GA, 30333, USA
SOURCE: Journal of Infectious Diseases (1999), 180(4),
1033-1042
CODEN: JIDIAQ; ISSN: 0022-1899
PUBLISHER: University of Chicago Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
TI Overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses
ST overexpression cancer **huntingtin interacting protein** HIP1 tumor marker; diagnosis anticancer prostate colon cancer HIP1
IT Animal cell line
(3T3, NIH/3T3, HIP1 has oncogenic activities in; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Hybridoma
(ATCC PTA-3901, PTA-3902, PTA-4071; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Animal cell line
(Colo 205, use in drug screening; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Nucleic acid hybridization
(DNA-mRNA, in situ; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Protein motifs
(ENTH domain, of HIP1, prospective drug binds to; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(HIP1 (huntingin interacting protein 1); overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Mus
(HIP1 knockout, model, use in drug screening; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Transformation, neoplastic
(HIP1 role in; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)
IT Gene, animal

RL: ANT (Analyte); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); REM (Removal or disposal); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

(HIP1, knock-out; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Proteins

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HIP1, mutant, with ENTH-domain deletion; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Probes (nucleic acid)

RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(HIP1-specific; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT mRNA

RL: ADV (Adverse effect, including toxicity); ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(HIP1; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Antibodies and Immunoglobulins

RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(HIP1; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Antisense nucleic acids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HIP1; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT PCR (polymerase chain reaction)

(RT-PCR (reverse transcription-PCR); overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Epidermal growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(activated by HIP1; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Blood plasma

Blood serum

(anal.; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Lipids, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(analogs, library, screening; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland, disease

(benign hyperplasia; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Hyperplasia
(benign prostatic; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Apoptosis
(cancer cell, induction; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Diagnosis
(cancer; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland, neoplasm
(carcinoma, metastasis; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland, neoplasm
(carcinoma; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Intestine
(colon, epithelium, HIP1 absent in normal; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Intestine, neoplasm
(colon; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Epithelium
(colonic, HIP1 absent in normal; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Fibroblast
(embryonic, mouse, use in drug screening; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland
(epithelium, HIP1 absent in normal; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT DNA sequences
(for ENTH-domain deletion-containing HIP1 protein; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Gene targeting
(gene knock-out, of HIP1 gene; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland, neoplasm
(identifying stage of; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Cell proliferation
(inhibition, cancer; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prostate gland, neoplasm

(intraepithelial, high-grade; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Phosphatidylinositols

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mimetics; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Diagnosis

(mol., cancer; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Antibodies and Immunoglobulins

RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal, HIP1; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Protein sequences

(of ENTH-domain deletion-containing HIP1 protein; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Antitumor agents

Blood analysis

Carcinoma

DNA microarray technology

Drug screening

Human

Mus

Northern blot hybridization

Nucleic acid hybridization

Susceptibility (genetic)

Test kits

Tumor markers

Urine analysis

(overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Prognosis

(progression of prostate cancer; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Epithelium

(prostatic, HIP1 absent in normal; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Carcinoma

(prostatic, metastasis; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Carcinoma

(prostatic; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Peptide library

(screening; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT Animal tissue

(tumor, anal.; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT 532767-22-9
 RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT 532767-21-8
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT 532767-23-0
 RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT 532767-20-7
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

IT 532770-64-2 532770-65-3, 6: PN: WO03043566 SEQID: 6 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses)

=> d ibib 2

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:417568 CAPLUS
 DOCUMENT NUMBER: 139:5159
 TITLE: Overexpressed in cancer of **huntingtin interacting protein**, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses
 INVENTOR(S): Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh
 PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043566	A2	20030530	WO 2002-US36175	20021112
WO 2003043566	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,			

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003124533 A1 20030703 US 2001-7047 20011206
CA 2467459 AA 20030530 CA 2002-2467459 20021112
EP 1527190 A2 20050504 EP 2002-793914 20021112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
US 2004265929 A1 20041230 US 2004-767325 20040129
WO 2005072457 A2 20050811 WO 2005-US3330 20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-335276P P 20011115
US 2001-7047 A 20011206
WO 2002-US36175 W 20021112
US 2004-767325 A 20040129

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.22	38.89

FILE 'PCTFULL' ENTERED AT 07:43:59 ON 01 DEC 2005
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 22 NOV 2005 <20051122/UP>
MOST RECENT UPDATE WEEK: 200546 <200546/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> KWIC format free of charge - SEE NEWS >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html <

=> s (HIP (w) 1) or (huntingtin interacting protein)

8220 HIP
3092 HIPS
10435 HIP
(HIP OR HIPS)
959046 1
116 HIP (W) 1
435 HUNTINGTIN
6 HUNTINGTINS
436 HUNTINGTIN
(HUNTINGTIN OR HUNTINGTINS)
36344 INTERACTING
127255 PROTEIN
107382 PROTEINS

```

140473 PROTEIN
      (PROTEIN OR PROTEINS)
106 HUNTINGTIN INTERACTING PROTEIN
      (HUNTINGTIN(W)INTERACTING(W)PROTEIN)
L20      203 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)

```

```

=> s autoantibod? or (anti ( ) antibod?)
      2743 AUTOANTIBOD?
164947 ANTI
      165 ANTIS
164978 ANTI
      (ANTI OR ANTIS)
82883 ANTIBOD?
      883 ANTI (W) ANTIBOD?
L21      3564 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)

```

```

=> s elicit (S) antibod?
      21422 ELICIT
      7303 ELICITS
      24440 ELICIT
      (ELICIT OR ELICITS)
82883 ANTIBOD?
L22      9992 ELICIT (S) ANTIBOD?

```

```

=> s antibod?
L23      82883 ANTIBOD?

```

```

=> s serum or sera or blood or urine
      83318 SERUM
      1356 SERUMS
      45571 SERA
113532 SERUM
      (SERUM OR SERUMS OR SERA)
      45571 SERA
      43 SERAS
      45585 SERA
      (SERA OR SERAS)
122899 BLOOD
      269 BLOODS
122912 BLOOD
      (BLOOD OR BLOODS)
      25180 URINE
      405 URINES
      25292 URINE
      (URINE OR URINES)
L24      178963 SERUM OR SERA OR BLOOD OR URINE

```

```

=> s 120 and 121
L25      8 L20 AND L21

```

```

=> s 120/ab
      663 HIP/AB
      139 HIPS/AB
      776 HIP/AB
      ((HIP OR HIPS)/AB)
230754 1/AB
      4 HIP/AB (W) 1/AB
      16 HUNTINGTIN/AB
      1 HUNTINGTINS/AB
      16 HUNTINGTIN/AB
      ((HUNTINGTIN OR HUNTINGTINS)/AB)
      2054 INTERACTING/AB
      22930 PROTEIN/AB

```



```

13064 PROTEINS/AB
31025 PROTEIN/AB
      ((PROTEIN OR PROTEINS)/AB)
2 HUNTINGTIN INTERACTING PROTEIN/AB
      ((HUNTINGTIN (W) INTERACTING (W) PROTEIN)/AB)
L26      6 ((HIP/AB (W) 1/AB) OR (HUNTINGTIN INTERACTING PROTEIN/AB))

=> s 120/clm
      1264 HIP/CLM
      906427 1/CLM
      16 HIP/CLM (W) 1/CLM
      78 HUNTINGTIN/CLM
      6066 INTERACTING/CLM
      47377 PROTEIN/CLM
      12 HUNTINGTIN INTERACTING PROTEIN/CLM
      ((HUNTINGTIN (W) INTERACTING (W) PROTEIN)/CLM)
L27      25 ((HIP/CLM (W) 1/CLM) OR (HUNTINGTIN INTERACTING PROTEIN/CLM))

=> s 126 or 127
L28      28 L26 OR L27

=> s 128 and 121
L29      0 L28 AND L21

=> s 123 (S) 124
L30      41122 L23 (S) L24

=> s (detect? or determin?) (S) 123
      313247 DETECT?
      516096 DETERMIN?
L31      55958 (DETECT? OR DETERMIN?) (S) L23

=> 131 and 128
L31 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 131 and 128
L32      14 L31 AND L28

=> s 132 not py>2003
      222501 PY>2003
L33      10 L32 NOT PY>2003

=> s cancer? or tumor or neoplas?
      73267 CANCER?
      52062 TUMOR
      32865 TUMORS
      57617 TUMOR
      (TUMOR OR TUMORS)
      21140 NEOPLAS?
L34      89447 CANCER? OR TUMOR OR NEOPLAS?

=> s 133 and 134
L35      8 L33 AND L34

=> s 131/clm
      107933 DETECT?/CLM
      158306 DETERMIN?/CLM
      32513 ANTIBOD?/CLM
L36      12578 ((DETECT?/CLM OR DETERMIN?/CLM) (S) (ANTIBOD?/CLM))

```

=> s 136 and 135
L37 5 L36 AND L35

=> s 137 and 127
L38 4 L37 AND L27

=> d ibib 1-4

L38 ANSWER 1 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003043566 PCTFULL ED 20030610 EW 200322
TITLE (ENGLISH): HIP1 **CANCER** MARKERS
TITLE (FRENCH): MARQUEURS DE **CANCER** HIP1
INVENTOR(S): ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203,
US [US, US];
MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI
48105, US [US, US];
ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102,
Ypsilanti, MI 48197, US [US, US]
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF MICHIGAN, 3003 S.
State Street, Ann Arbor, MI 48109, US [US, US], for all
designates States except US;
ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203,
US [US, US], for US only;
MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI
48105, US [US, US], for US only;
ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102,
Ypsilanti, MI 48197, US [US, US], for US only
AGENT: CARROLL, Peter, G.\$, Medlen & Carroll, LLP, Suite 350,
101 Howard Street, San Francisco, CA 94105\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2003043566	A2	20030530
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-US36175	A	20021112
PRIORITY INFO.:	US 2001-60/335,276		20011115
	US 2001-10/007,047		20011206

L38 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2000055633 PCTFULL ED 20020515
TITLE (ENGLISH): NOVEL METHODS OF DIAGNOSING COLORECTAL **CANCER**
, COMPOSITIONS, AND METHODS OF SCREENING FOR COLORECTAL
CANCER MODULATORS
TITLE (FRENCH): METHODES PERMETTANT DE DIAGNOSTIQUER DU **CANCER**
COLO-RECTAL, COMPOSITIONS, ET METHODES PERMETTANT DE
DETECTER DES MODULATEURS DU **CANCER**
COLO-RECTAL
INVENTOR(S): MACK, David;
GISH, Kurt, C.;
WILSON, Keith, E.

PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055633	A2	20000921

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG

APPLICATION INFO.:
PRIORITY INFO.:

WO 2000-US7044	A	20000315
US 1999-09/268,866		19990315
US 1999-09/436,983		19991109
US 1999-09/435,945		19991109
US 1999-09/450,857		19991129
US 1999-09/453,850		19991202
US 2000-09/493,444		20000128

L38 ANSWER 3 OF 4
ACCESSION NUMBER:
TITLE (ENGLISH):

PCTFULL COPYRIGHT 2005 Univentio on STN
2000055629 PCTFULL ED 20020515
NOVEL METHODS OF DIAGNOSING AND TREATING BREAST
CANCER, COMPOSITIONS, AND METHODS OF SCREENING
FOR BREAST **CANCER** MODULATORS

TITLE (FRENCH):

NOUVELLES TECHNIQUES PERMETTANT DE TRAITER ET DE
DIAGNOSTIQUER LE **CANCER** DU SEIN, COMPOSITIONS
ET TECHNIQUES DE CRIBLAGE POUR MODULATEURS DE
CANCER DU SEIN

INVENTOR(S):

MACK, David;
GISH, Kurt, C.
EOS BIOTECHNOLOGY, INC.;
MACK, David;
GISH, Kurt, C.

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.:
DOCUMENT TYPE:
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055629	A2	20000921

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
GW ML MR NE SN TD TG

APPLICATION INFO.:
PRIORITY INFO.:

WO 2000-US6952	A	20000315
US 1999-09/268,865		19990315
US 1999-09/439,878		19991112
US 1999-09/440,370		19991112
US 1999-09/440,493		19991115
US 1999-09/440,676		19991116
US 1999-09/440,677		19991116
US 1999-09/450,810		19991129
US 1999-09/453,137		19991202
US 2000-09/453,137		20000308

L38 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1999015626 PCTFULL ED 20020515
 TITLE (ENGLISH): IDENTIFICATION OF HOP-1 AND USES THEREOF
 TITLE (FRENCH): IDENTIFICATION DE HOP-1 ET SES UTILISATIONS
 INVENTOR(S): GREENWALD, Iva;
 LI, Xiajun
 PATENT ASSIGNEE(S): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW
 YORK
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9915626	A1	19990401

DESIGNATED STATES
 W: AU CA JP MX AT BE CH CY DE DK ES FI FR GB GR IE IT LU
 MC NL PT SE
 APPLICATION INFO.: WO 1998-US20030 A 19980925
 PRIORITY INFO.: US 1997-08/937,834 19970925

=> d clm 2

L38 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
 CLM data too large for display

=> d kwic 2

L38 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
 TIEN NOVEL METHODS OF DIAGNOSING COLORECTAL **CANCER**, COMPOSITIONS,
 AND METHODS OF SCREENING FOR COLORECTAL **CANCER** MODULATORS
 TIFR METHODES PERMETTANT DE DIAGNOSTIQUER DU **CANCER** COLO-RECTAL,
 COMPOSITIONS, ET METHODES PERMETTANT DE DETECTER DES MODULATEURS DU
CANCER COLO-RECTAL
 ABEN Described herein are methods that can be used for diagnosis and
 prognosis of colorectal **cancer**.
 Also described herein are methods that can be used to screen candidate
 bioactive agents for the
 ability to modulate colorectal **cancer**. Additionally, methods
 and molecular targets (genes and their
 products) for therapeutic intervention in colorectal and other
cancers are described.
 ABFR L'invention concerne des methodes utiles pour le diagnostic et le
 pronostic du **cancer**
 colo-rectal. L'invention concerne egalement des methodes permettant de
 detecter la capacite que
 possedent des agents bioactifs candidats pour moduler un **cancer**
 colo-rectal. L'invention concerne en
 outre des methodes et des cibles moleculaires (genes et leurs produits)
 permettant d'effectuer une
 intervention therapeutique pour lutter contre le **cancer**
 colo-rectal et d'autres types **cancers**.
 DETD data too large for display
 DETD data too large for display
 DETD data too large for display
 DETD data too large for display

[illegible]

[illegible]

[illegible]

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

CLM data too large for display

=> file dissab

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.79

53.68

FILE 'DISSABS' ENTERED AT 07:50:33 ON 01 DEC 2005

COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 23 NOV 2005 (20051123/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=> s (HIP (w) 1) or (huntingtin interacting protein)

1975 HIP

185 HIPS

2094 HIP

(HIP OR HIPS)

360771 1

4 HIP (W) 1

35 HUNTINGTIN

9222 INTERACTING

76083 PROTEIN
 41788 PROTEINS
 87948 PROTEIN
 (PROTEIN OR PROTEINS)
 6 HUNTINGTIN INTERACTING PROTEIN
 (HUNTINGTIN(W) INTERACTING(W) PROTEIN)
 L39 9 (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)

=> s autoantibod? or (anti () antibod?)
 500 AUTOANTIBOD?
 25594 ANTI
 9 ANTIS
 25599 ANTI
 (ANTI OR ANTIS)
 19247 ANTIBOD?
 8 ANTI (W) ANTIBOD?
 L40 508 AUTOANTIBOD? OR (ANTI (W) ANTIBOD?)

=> s l39 and l40
 L41 0 L39 AND L40

=> s antibod?
 L42 19247 ANTIBOD?

=> s (detect? or determin?) (S) l42
 81957 DETECT?
 347672 DETERMIN?
 L43 7556 (DETECT? OR DETERMIN?) (S) L42

=> s l43 and l39
 L44 0 L43 AND L39

=> s humoral
 L45 1618 HUMORAL

=> s l45 an dl39
 MISSING OPERATOR L45 AN
 The search profile that was entered contains terms or
 nested terms that are not separated by a logical operator.

=> s l45 and l39
 L46 0 L45 AND L39

=> d his

(FILE 'HOME' ENTERED AT 07:36:33 ON 01 DEC 2005)

FILE 'MEDLINE' ENTERED AT 07:36:44 ON 01 DEC 2005

L1 139 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
 L2 49578 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
 L3 1 S L2 AND L1
 L4 32818 S HUMORAL
 L5 0 S L4 AND L1
 L6 2204 S ELICIT (S) ANTIBOD?
 L7 0 S L6 AND L1
 L8 701293 S ANTIBOD?
 L9 2566559 S SERUM OR SERA OR BLOOD OR URINE
 L10 94348 S L9 (S) L8
 L11 2 S L10 AND L1

FILE 'CAPLUS' ENTERED AT 07:39:59 ON 01 DEC 2005

L12 173 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
 L13 18079 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)

L14 1 S L12 AND L13
 L15 2567 S ELICIT (S) ANTIBOD?
 L16 448177 S ANTIBOD?
 L17 1569955 S SERUM OR SERA OR BLOOD OR URINE
 L18 71367 S L16 (S) L17
 L19 3 S L18 AND L12

FILE 'PCTFULL' ENTERED AT 07:43:59 ON 01 DEC 2005

L20 203 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
 L21 3564 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
 L22 9992 S ELICIT (S) ANTIBOD?
 L23 82883 S ANTIBOD?
 L24 178963 S SERUM OR SERA OR BLOOD OR URINE
 L25 8 S L20 AND L21
 L26 6 S L20/AB
 L27 25 S L20/CLM
 L28 28 S L26 OR L27
 L29 0 S L28 AND L21
 L30 41122 S L23 (S) L24
 L31 55958 S (DETECT? OR DETERMIN?) (S) L23
 L32 14 S L31 AND L28
 L33 10 S L32 NOT PY>2003
 L34 89447 S CANCER? OR TUMOR OR NEOPLAS?
 L35 8 S L33 AND L34
 L36 12578 S L31/CLM
 L37 5 S L36 AND L35
 L38 4 S L37 AND L27

FILE 'DISSABS' ENTERED AT 07:50:33 ON 01 DEC 2005

L39 9 S (HIP (W) 1) OR (HUNTINGTIN INTERACTING PROTEIN)
 L40 508 S AUTOANTIBOD? OR (ANTI () ANTIBOD?)
 L41 0 S L39 AND L40
 L42 19247 S ANTIBOD?
 L43 7556 S (DETECT? OR DETERMIN?) (S) L42
 L44 0 S L43 AND L39
 L45 1618 S HUMORAL
 L46 0 S L45 AND L39

CCESSION NUMBER: 2003043566 PCTFULL ED 20030610 EW 200322
 TITLE (ENGLISH): HIP1 **CANCER** MARKERS
 TITLE (FRENCH): MARQUEURS DE **CANCER** HIP1
 INVENTOR(S): ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203, US [US, US];
 MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI 48105, US [US, US];
 ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102, Ypsilanti, MI 48197, US [US, US]
 PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF MICHIGAN, 3003 S. State Street, Ann Arbor, MI 48109, US [US, US], for all designates States except US;
 ROSS, Theodora, 4870 Lytham Lane, Ann Arbor, MI 48203, US [US, US], for US only;
 MIZUKAMI, Ikuko, 5225 Earhart Road, Ann Arbor, MI 48105, US [US, US], for US only;
 ROA, Dinesh, 2045 Arbor Circle, W., Apt. 102, Ypsilanti, MI 48197, US [US, US], for US only
 AGENT: CARROLL, Peter, G.\$, Medlen & Carroll, LLP, Suite 350, 101 Howard Street, San Francisco, CA 94105\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003043566	A2	20030530

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
 SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
NL PT SE SK TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US36175 A 20021112

PRIORITY INFO.:

US 2001-60/335,276 20011115

US 2001-10/007,047 20011206

L38 ANSWER 2 OF 4

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2005 Univentio on STN

TITLE (ENGLISH):

2000055633 PCTFULL ED 20020515

NOVEL METHODS OF DIAGNOSING COLORECTAL **CANCER**
 , COMPOSITIONS, AND METHODS OF SCREENING FOR COLORECTAL
CANCER MODULATORS

TITLE (FRENCH):

METHODES PERMETTANT DE DIAGNOSTIQUER DU **CANCER**
 COLO-RECTAL, COMPOSITIONS, ET METHODES PERMETTANT DE
 DETECTER DES MODULATEURS DU **CANCER**
 COLO-RECTAL

INVENTOR(S):

MACK, David;
 GISH, Kurt, C.;
 WILSON, Keith, E.

PATENT ASSIGNEE(S):

EOS BIOTECHNOLOGY, INC.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000055633	A2	20000921

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE

DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
 UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
 ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US7044 A 20000315
 PRIORITY INFO.: US 1999-09/268,866 19990315
 US 1999-09/436,983 19991109
 US 1999-09/435,945 19991109
 US 1999-09/450,857 19991129
 US 1999-09/453,850 19991202
 US 2000-09/493,444 20000128

L38 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 2000055629 PCTFULL ED 20020515
 TITLE (ENGLISH): NOVEL METHODS OF DIAGNOSING AND TREATING BREAST
CANCER, COMPOSITIONS, AND METHODS OF SCREENING
 FOR BREAST **CANCER** MODULATORS
 TITLE (FRENCH): NOUVELLES TECHNIQUES PERMETTANT DE TRAITER ET DE
 DIAGNOSTIQUER LE **CANCER** DU SEIN, COMPOSITIONS
 ET TECHNIQUES DE CRIBLAGE POUR MODULATEURS DE
CANCER DU SEIN
 INVENTOR(S): MACK, David;
 GISH, Kurt, C.
 PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC.;
 MACK, David;
 GISH, Kurt, C.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2000055629	A2	20000921

DESIGNATED STATES
 W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ
 UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG
 ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
 FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
 GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US6952 A 20000315
 PRIORITY INFO.: US 1999-09/268,865 19990315
 US 1999-09/439,878 19991112
 US 1999-09/440,370 19991112
 US 1999-09/440,493 19991115
 US 1999-09/440,676 19991116
 US 1999-09/440,677 19991116
 US 1999-09/450,810 19991129
 US 1999-09/453,137 19991202
 US 2000-09/453,137 20000308

L38 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1999015626 PCTFULL ED 20020515
 TITLE (ENGLISH): IDENTIFICATION OF HOP-1 AND USES THEREOF
 TITLE (FRENCH): IDENTIFICATION DE HOP-1 ET SES UTILISATIONS
 INVENTOR(S): GREENWALD, Iva;
 LI, Xiajun
 PATENT ASSIGNEE(S): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW
 YORK